Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: J Robert McCorkle, Justin W Gorski, Jinpeng Liu, McKayla B Riggs, Anthony B McDowell, Nan Lin, Chi Wang, Frederick R Ueland, Jill M Kolesar
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/5ad0341705cb49caa5d265241a23a1bf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares